Association of a High-Efficiency Particulate Air Filter COVID-19 Testing Booth With Testing Capacity, Cost Per Test Acquired, and Use of Personal Protective Equipment
Sign Up to like & getrecommendations! Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.17698
Abstract: This quality improvement study compares COVID-19 testing throughput, personal protective equipment use, and cost per test before vs after the introduction of high-efficiency particulate air–filtered, positive-pressure Hexapod personal protection booths at a hospital in Boston,… read more here.
Keywords: per test; high efficiency; personal protective; protective equipment ... See more keywords
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.16058
Abstract: This cross-sectional study evaluates the cost per event averted in adjuvant cancer trials between January 2018 and March 2022. read more here.
Keywords: cost per; per event; cancer trials; event averted ... See more keywords
Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price
Sign Up to like & getrecommendations! Published in 2018 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-018-0703-z
Abstract: Background Spending on biological agents has risen dramatically due to the high cost of the drugs and the increased prevalence of spondyloarthritis. Objective To evaluate the annual cost per patient and cost for each biological… read more here.
Keywords: annual cost; biological agents; per patient; spondyloarthritis ... See more keywords
Number Needed to Treat and Cost Per Responder Analysis of Anti-CGRP Monoclonal Antibodies for Migraine Prevention in Adults for Whom Prior Preventive Treatments have Failed
Sign Up to like & getrecommendations! Published in 2025 at "Advances in Therapy"
DOI: 10.1007/s12325-025-03348-8
Abstract: Four monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) signaling are approved for migraine prevention and commonly prescribed/reimbursed after the failure of repurposed anti-migraine medications. Participants achieving clinical response [e.g., ≥ 50% monthly migraine days… read more here.
Keywords: anti cgrp; cost per; per responder; migraine prevention ... See more keywords
Metabolic Syndrome Has a Negative Impact on Cost Utility Following Spine Surgery.
Sign Up to like & getrecommendations! Published in 2019 at "World neurosurgery"
DOI: 10.1016/j.wneu.2019.12.053
Abstract: OBJECTIVE Investigate the differences in spine surgery cost for metabolic syndrome patients. METHODS Included: Patients ≥18, undergoing fusion. Patients were divided into cervical, thoracic, and lumbar groups based on their upper instrumented vertebrae (UIV). Metabolic… read more here.
Keywords: spine surgery; non mets; surgery; metabolic syndrome ... See more keywords
Evaluating drug cost per responder and number needed to treat associated with lixisenatide on top of glargine when compared to rapid-acting insulin intensification regimens on top of glargine, in patients with type 2 diabetes in the UK, Italy, and Spain
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2017.1304395
Abstract: Abstract Objectives: This study investigated the cost per responder and number needed to treat (NNT) in type 2 diabetes mellitus (T2DM) patients for lixisenatide compared to insulin intensification regimens using composite endpoints in the UK,… read more here.
Keywords: per responder; top glargine; cost per; responder ... See more keywords
Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of medical economics"
DOI: 10.1080/13696998.2025.2503661
Abstract: Abstract Introduction Mirikizumab, approved for the treatment of moderately to severely active ulcerative colitis (UC), may be prescribed in a similar placement to ustekinumab in second-line settings. Payers may compare the economic value when making… read more here.
Keywords: mirikizumab; per remission; treatment; cost per ... See more keywords
Cost per responder of Adalimumab biosimilars MSB11022 and ABP 501 versus the originator and methotrexate in chronic plaque psoriasis
Sign Up to like & getrecommendations! Published in 2022 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2022.2070428
Abstract: ABSTRACT Background Pharmacoeconomic studies comparing the cost of adalimumab biosimilars versus the originator and conventional drugs in psoriasis are lacking. Research design and methods To assess the cost per responder of adalimumab biosimilars versus the… read more here.
Keywords: cost per; responder; cost; adalimumab biosimilars ... See more keywords
Economic evaluation of the e-Health StandingTall balance exercise programme for fall prevention in people aged 70 years and over.
Sign Up to like & getrecommendations! Published in 2022 at "Age and ageing"
DOI: 10.1093/ageing/afac130
Abstract: BACKGROUND globally, falls and fall-related injuries are the leading cause of injury-related morbidity and mortality in older people. In our ageing society healthcare costs are increasing, therefore programmes that reduce falls and are considered value… read more here.
Keywords: cost per; fall; health; cost ... See more keywords
Cost and Cost-Effectiveness of Four Specialized Nutritious Foods for Treatment of Moderate Acute Malnutrition in Sierra Leone (P10-142-19).
Sign Up to like & getrecommendations! Published in 2019 at "Current developments in nutrition"
DOI: 10.1093/cdn/nzz034.p10-142-19
Abstract: Objectives To estimate cost-effectiveness of 4 specialized nutritious foods (SNF) for Moderate Acute Malnutrition (MAM) treatment in children under five in Pujehun District, Sierra Leone. Methods In a cluster randomized trial, a mobile supplementary feeding… read more here.
Keywords: child; cost per; oil; cost effectiveness ... See more keywords
Outpatient Therapies for COVID-19: How Do We Choose?
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac008
Abstract: Abstract Background Several outpatient coronavirus disease 2019 (COVID-19) therapies have reduced hospitalization in randomized controlled trials. The choice of therapy may depend on drug efficacy, toxicity, pricing, availability, and available infrastructure. To facilitate comparative decision-making,… read more here.
Keywords: risk; per hospitalization; cost per; cost ... See more keywords